Urgent.News

What's breaking now, across hundreds of outlets.

Health & Medicine

‘Too good to be true’: Biotech company’s paper on Parkinson’s retracted for data manipulation

A Cell Press journal has retracted a paper on Parkinson’s disease following the discovery that the first author manipulated data in the work. The retraction notice in Cell Reports states one of the coauthors found the first author, Madhuja Samaddar, changed data points to reduce variability and improve statistical significance in ways that affect some … Continue reading ‘Too good to be true’:…

‘Too good to be true’: Biotech company’s paper on Parkinson’s retracted for data manipulation

A Cell Press journal has retracted a paper on Parkinson's disease due to data manipulation discovered by a coauthor. The first author, Madhuja Samaddar, altered data points to reduce variability and enhance statistical significance, impacting some figures and conclusions. Samaddar, a scientist at Denali Therapeutics, studied the impact of polyamines on an enzyme that breaks down fat in cell and mouse models of neurologic diseases like Parkinson's.

The study, published in 2025, explored the connection between lysosomal dysfunction and neurodegeneration. Samaddar was the lead author on this paper, which is the only one for which she held this position during her time at Denali. Denali's spokesperson described the issue as "isolated" and stated that the research was not used to support any of the company's therapeutic programs.

Elsevier, the publisher, declined to comment, referring to their retraction policies. Marja Jäättelä, a researcher at the Danish Cancer Society, commented on the unusual evenness of the manipulated data and the potential pressure on researchers to produce favorable results. The paper did not significantly stand out to her, as the authors presented mechanistic explanations of how a defect in polyamines could lead to lysosomal dysfunction.

Jäättelä emphasized that while data variation is common in biology, excessive modification to fit a hypothesis is not acceptable. Marc Tessier-Lavigne, a cofounder of Denali and former president of Stanford University, was on the company's board when Samaddar worked there but did not conduct or oversee research. Samaddar, who has no other retractions in the Retraction Watch database, previously worked at Calico Life Sciences and trained under Patrick D’Silva at the Indian Institute of Science. D’Silva has not commented on the current issue.

Rewritten by urgent.news; may contain errors — check the original.

Read the original at retractionwatch.com →

Report a problem with this story

More in Health & Medicine

More from Monday 16 November →